Synendos Therapeutics
PrivateLast Round
Grant
Oct 30, 2024
Total Funding Raised
$32.2M
Company Overview
Synendos Therapeutics is a neuroscience company developing therapies for neuropsychiatric and neurological disorders by modulating the endocannabinoid system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synendos Therapeutics Comparables
Compare Synendos Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| H. Lundbeck A/S | 77% | |
| Roche Holding | 71% | |
| Bristol Myers Squibb | 71% | |
Synendos Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 30, 2024 | ||||
| Grant | Apr 20, 2021 | ||||
| Series A | Nov 12, 2020 | ||||
| Grant | Oct 1, 2020 | ||||
| Grant | Nov 1, 2019 | ||||
Grant | Aug 1, 2019 |
Key People
Founding team and executive leadership
Synendos Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gebert Rüf Stiftung | Grant |
| Ysios Capital | Series A, Grant |
| Eurostars SME programme | Grant |
| BERNINA BioInvest AG | Series A |
| Innosuisse | Grant |
| BaseLaunch | Accelerator |
| Sunstone Life Science Ventures | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 12, 2025
Dr. George Garibaldi appointed as new Chief Medical Officer.
- Nov 12, 2020
$26M round led by Kurma Partners and Sunstone Life Science Ventures.
Synendos Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Synendos Therapeutics's valuation, stock price, and market status.